Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction

Neurohormonal and clinical sex differences in heart failure

(2013) S. Meyer et al.   EUROPEAN HEART JOURNAL

B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction

(2013) Dirk J. van Veldhuisen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inflammation and anaemia in a broad spectrum of patients with heart failure

(2012) Lennaert Kleijn et al.   HEART

Lack of Tissue Inhibitor of Metalloproteinases 2 Leads to Exacerbated Left Ventricular Dysfunction and Adverse Extracellular Matrix Remodeling in Response to Biomechanical Stress

(2011) Vijay Kandalam et al.   CIRCULATION

The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure

(2011) Douwe Postmus et al.   EUROPEAN JOURNAL OF HEART FAILURE

Increased level of soluble syndecan-1 in serum correlates with myocardial expression in a rat model of myocardial infarction

(2011) Juan Lei et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

(2010) Rudolf A. de Boer et al.   ANNALS OF MEDICINE

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

(2010) B. A. Borlaug et al.   EUROPEAN HEART JOURNAL

Syndecan-1 Amplifies Angiotensin II–Induced Cardiac Fibrosis

(2010) Mark W.M. Schellings et al.   HYPERTENSION

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

(2010) Michael J. Pencina et al.   STATISTICS IN MEDICINE

Effect of Moderate or Intensive Disease Management Program on Outcome in Patients With Heart FailureCoordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH)

(2008) Tiny Jaarsma   ARCHIVES OF INTERNAL MEDICINE